Soluble Factors Released by Peripheral Blood-derived CAR-NK Cells Cause Bystander Myeloid Cell Activation

Overview

Journal Front Immunol

Date 2025 Jan 8

PMID 39776903

Authors

Supreet Khanal

Alan Baer

Md Kamal Hossain

Winston Colon-Moran

Santosh Panthi

Nirjal Bhattarai

Affiliations

Soon will be listed here.

Abstract

Introduction: CAR-T cell therapy is associated with life-threatening inflammatory toxicities, partly due to the activation and secretion of inflammatory cytokines by bystander myeloid cells (BMCs). However, due to limited clinical data, it is unclear whether CAR-NK cells cause similar toxicities.

Methods: We characterized the soluble factors (SFs) released by activated human CAR-T and CAR-NK cells and assessed their role in BMC activation (BMCA).

Results: We found that SFs from both activated, peripheral blood-derived CAR-T (PB-CAR-T) and CAR-NK (PB-CAR-NK) cells induced BMCA; however, PB-CAR-NK cells caused significantly lower BMCA compared to PB-CAR-T cells. Interestingly, SFs from cord-blood-derived (CB) NK cells caused little to no BMCA, consistent with previous clinical studies showing minimal inflammatory toxicity with CB-CAR-NK cells. Comparative analysis of SFs released by PB-NK and PB-CAR-NK cells following CAR-dependent and CAR-independent activation revealed several candidate factors with the potential to cause BMCA. Antibody-mediated neutralization studies identified a combination of four factors that contribute to PB-CAR-NK cell-mediated BMCA. siRNA-mediated knockdown studies confirmed that inactivating these four factors in PB-CAR-NK cells significantly reduces BMCA. Importantly, neutralization or knockdown of these four factors did not affect CAR-NK cell potency.

Discussion: These data suggest that specific SFs released by PB-CAR-NK cells activate BMCs and have the potential to contribute to inflammatory toxicities. Furthermore, inactivation of these four factors in PB-CAR-NK cells could reduce inflammatory toxicities and improve safety of PB-CAR-NK cell therapy without compromising potency.

References

Liu F, Endo Y, Romantseva T, Wu W, Akue A, Shen R . T cell-derived soluble glycoprotein GPIbα mediates PGE production in human monocytes activated with the vaccine adjuvant MDP. Sci Signal. 2019; 12(602). DOI: 10.1126/scisignal.aat6023. View

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

Lamture G, Baer A, Fischer J, Colon-Moran W, Bhattarai N . TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes. J Immunother. 2021; 45(3):139-149. PMC: 8906249. DOI: 10.1097/CJI.0000000000000402. View

Gust J, Ponce R, Liles W, Garden G, Turtle C . Cytokines in CAR T Cell-Associated Neurotoxicity. Front Immunol. 2021; 11:577027. PMC: 7772425. DOI: 10.3389/fimmu.2020.577027. View

Morris E, Neelapu S, Giavridis T, Sadelain M . Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2021; 22(2):85-96. PMC: 8127450. DOI: 10.1038/s41577-021-00547-6. View

Handgretinger R, Lang P, Andre M . Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016; 127(26):3341-9. DOI: 10.1182/blood-2015-12-629055. View

Fauriat C, Long E, Ljunggren H, Bryceson Y . Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2009; 115(11):2167-76. PMC: 2844017. DOI: 10.1182/blood-2009-08-238469. View

Sterner R, Sakemura R, Cox M, Yang N, Khadka R, Forsman C . GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2018; 133(7):697-709. PMC: 6376281. DOI: 10.1182/blood-2018-10-881722. View

Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G . CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol. 2001; 31(10):3121-7. DOI: 10.1002/1521-4141(2001010)31:10<3121::aid-immu3121>3.0.co;2-4. View

10.

Baer A, Colon-Moran W, Xiang J, Stapleton J, Bhattarai N . Src-family kinases negatively regulate NFAT signaling in resting human T cells. PLoS One. 2017; 12(10):e0187123. PMC: 5658144. DOI: 10.1371/journal.pone.0187123. View

11.

Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A . The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012; 73(3):248-57. DOI: 10.1016/j.humimm.2011.12.015. View

12.

Neelapu S, Tummala S, Kebriaei P, Wierda W, Locke F, Lin Y . Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018; 15(4):218. PMC: 6716606. DOI: 10.1038/nrclinonc.2018.20. View

13.

Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J . Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial. Nat Med. 2024; 30(3):772-784. PMC: 10957466. DOI: 10.1038/s41591-023-02785-8. View

14.

Momayyezi P, Malmberg K, Hammer Q . Small Interfering RNA Delivery Into Primary Human Natural Killer Cells for Functional Gene Analyses. Curr Protoc. 2022; 2(11):e613. DOI: 10.1002/cpz1.613. View

15.

Giavridis T, van der Stegen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M . CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24(6):731-738. PMC: 6410714. DOI: 10.1038/s41591-018-0041-7. View

16.

Choi I, Yoon S, Park S, Kim H, Jung S, Kang Y . Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia. Biol Blood Marrow Transplant. 2016; 22(11):2065-2076. DOI: 10.1016/j.bbmt.2016.08.008. View

17.

Li M, Lin Z, Hu M, Kang L, Wu X, Chen Q . Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report. Biomark Res. 2020; 8:36. PMC: 7457525. DOI: 10.1186/s40364-020-00216-1. View

18.

Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J . Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J Biol Chem. 2019; 294(14):5430-5437. PMC: 6462525. DOI: 10.1074/jbc.AC119.007558. View

19.

Cooley S, He F, Bachanova V, Vercellotti G, DeFor T, Curtsinger J . First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 2019; 3(13):1970-1980. PMC: 6616260. DOI: 10.1182/bloodadvances.2018028332. View

20.

Liu E, Marin D, Banerjee P, Macapinlac H, Thompson P, Basar R . Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020; 382(6):545-553. PMC: 7101242. DOI: 10.1056/NEJMoa1910607. View